skip to search skip to navigation skip to main content

Archive: May 2017

Early detection is key to increase the survival rate of prostate cancer patients

03rd May 2017 in Product Launches

7% of the Egyptian male population are within the age group at risk for prostate cancer[1] Egyptian men who are diagnosed with prostate cancer are 7.2 times more likely to die from the disease as compared with the USA[2] Astellas Pharma launched Xtandi™ – enabling physicians to better tailor prostate cancer disease management according to…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2018 Astellas Pharma